Zhendong Zheng,Shuxian Qu,Xiaoxia Chen,Yongye Liu,Ying Piao,Yaling Han,Xiaodong Xie. Comparison of vinorelbine plus cisplatin withvinorelbine plus capecitabine in patients withanthracyclines- and taxanes-refractory advanced breast cancer. Oncol Transl Med, 2014, 13: 165-168.
Comparison of vinorelbine plus cisplatin withvinorelbine plus capecitabine in patients withanthracyclines- and taxanes-refractory advanced breast cancer
  
View Full Text  View/Add Comment  Download reader
KeyWord:capecitabine; vinorelbine; cisplatin; advanced breast cancer
Author NameAffiliation
Zhendong Zheng Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110840, China 
Shuxian Qu Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110841, China 
Xiaoxia Chen Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110842, China 
Yongye Liu Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110843, China 
Ying Piao Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110844, China 
Yaling Han Department of Cardiology, Institute of Cardiovascular Research of General Hospital of Shenyang Military Region, Shenyang 110840, China 
Xiaodong Xie Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110840, China 
Hits: 4781
Download times: 5647
Abstract:
      Objective: The aim of our study was to compare the efficacy and toxicities of vinorelbine plus cisplatin (NP) regimen with that of vinorelbine plus capecitabine (NX) regimen in the treatment of anthracycline- and taxane-refractory advanced breast cancer. Methods: Forty-six patients with anthracycline- and taxane-refractory advanced breast cancer were equally randomized into a NP group (n = 23) and a NX group (n = 23). Response rates and toxicities were evaluated after 2 cycles of chemotherapy. Results: The overall response rate were 48.0% in both groups. There were no significant differences in disease control rates (78.0% vs. 83%) or 1-year survival rates (54.6% vs. 55.9%). The main adverse events were bone marrow depression and gastrointestinal reaction, and no significant difference was found in toxicities between the groups. Conclusion: For anthracycline- and taxane-refractory advanced breast cancer, NP and NX regimens exerted similar curative effects with acceptable toxicity.
Close